secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibrx, Inc. (—)
CIK:        0001739614
Form:       8-K
Filed at:   2024-05-30T23:59:59+00:00
Accession:  0001104659-24-066650
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sanofi completes acquisition of Inhibrx for $30/share + $5 CVR; stock delisted
------------------------------------------------------------------------------

- Shareholders received $30 cash plus one CVR per share; CVR pays $5 upon FDA approval of INBRX-101 by June 30, 2027.
- Pre-merger, Inhibrx spun off 92% of Inhibrx Biosciences (SpinCo) to stockholders at 1 SpinCo share per 4 INBX shares.
- Aggregate merger consideration approximately $2 billion, financed by Sanofi from existing cash.
- Terminated and repaid $223.2 million loan with Oxford Finance, including prepayment penalties.
- Board and officers resigned; Sanofi appointees took control; stock to be delisted from Nasdaq.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739614/000110465924066650/0001104659-24-066650-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739614/000110465924066650/tm243190d20_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-066650

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer